PT  - JOURNAL ARTICLE
AU  - Konstantinos Kostikas
AU  - Huib A. M. Kerstjens
AU  - Jorge F. Maspero
AU  - Kenneth R. Chapman
AU  - Richard N. Van Zyl-Smit
AU  - Motoi Hosoe
AU  - Ana-Maria Tanase
AU  - Abhijit Pethe
AU  - Ioannis Kottakis
AU  - Peter D'Andrea
TI  - Mometasone/indacaterol/glycopyrronium (MF/IND/GLY) improves lung function and reduces exacerbations in patients with asthma, independent of baseline airflow limitation: Results from IRIDIUM study
AID  - 10.1183/13993003.congress-2021.PA3392
DP  - 2021 Sep 05
TA  - European Respiratory Journal
PG  - PA3392
VI  - 58
IP  - suppl 65
4099  - http://erj.ersjournals.com/content/58/suppl_65/PA3392.short
4100  - http://erj.ersjournals.com/content/58/suppl_65/PA3392.full
SO  - Eur Respir J2021 Sep 05; 58
AB  - Introduction: This post hoc analysis from IRIDIUM study evaluated if improvements with high-dose MF/IND/GLY (160/150/50µg) once-daily (o.d.) vs high-dose MF/IND (320/150µg) o.d. and high-dose fluticasone/salmeterol (FLU/SAL; 500/50µg) twice-daily in asthma pts were dependent on severity of airflow limitationMethods: IRIDIUM (NCT02571777) was 52-wk, randomised, double-blind, double-dummy study in pts with symptomatic asthma (ACQ-7≥1.5), ≥1 exacerbation in previous year and FEV1 <80%. Pts were categorised into subgroups based on severity of baseline airflow limitation (predicted pre-bronchodilator FEV1<40%, 40–60%, 60–80%) and evaluated for improvements in trough FEV1 at Wk 26 and reduction in exacerbation over 52 wks.Results: In all subgroups, high-dose MF/IND/GLY showed greater improvement in trough FEV1 and reduction in annualised rate of exacerbations vs high-dose FLU/SAL, and greater improvement in trough FEV1 vs high-dose MF/IND, which was in line with overall population (Table). A proportion of pts did not normalise their lung function even after maximal bronchodilation and prolonged steroids, suggesting an element of fixed airway obstructionConclusion: Improvements in lung function and exacerbations with high-dose MF/IND/GLY vs high-dose MF/IND and FLU/SAL were independent of severity of airflow limitation at baseline FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3392.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).